Obesity is increasingly common before and after liver transplantation (LT), yet optimal management remains unclear. The aim of this study was to analyze the long-term outcomes for obese patients undergoing LT, including a noninvasive weight loss program and combined LT and sleeve gastrectomy (SG). Since 2006, all patients referred for LT with a body mass index (BMI) 35 kg/m 2 were enrolled. Patients who achieved weight loss (BMI <35) underwent LT alone, and those who did not underwent simultaneous LT 1 SG. Analysis of long-term outcomes for patients 3 years posttransplant was performed. Since 2006, there were 36 in the weight loss intervention (LT cohort) and 13 in the LT 1 SG cohort with >3 years of follow-up, whereas overall, a total of 29 patients underwent LT 1 SG. Patients in the LT cohort had less severe obesity at enrollment (40.0 6 2.7 vs. LT 1 SG cohort 46.0 6 4.5; P < 0.001). In the LT cohort, 83.3% (30 of 36) achieved >10% loss in total body weight (TBW) pre-LT. Three years posttransplant, 29.4% of patients in the LT cohort maintained >10% loss in TBW, whereas 100% of the LT 1 SG patients did (P < 0.001). Patients who underwent LT 1 SG maintained a significantly higher percentage of total body weight loss after 3 years of follow-up (LT cohort 3.9 6 13.3% vs. LT 1 S G cohort 34.8 6 17.3%; P < 0.001). Patients in the LT 1 SG also had a lower prevalence of hypertension, insulin resistance, and hepatic steatosis and required fewer antihypertensive medications and lipid agents at last follow-up. Conclusion: Whereas weight loss before transplantation was achieved by obese patients, weight regain was common in the LT cohort. Combined LT 1 SG resulted in more effective and more durable weight loss, as well as fewer metabolic complications at last follow-up. (HEPATOLOGY 2018; 68:485-495).
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O besity is a world-wide epidemic with major economic implications. (1) The prevalence of obesity, as defined by a body mass index (BMI) 30, in the United States is estimated to be 34.9%. (2) The impact of the obesity epidemic on the incidence of liver disease is increasing, either as a primary (nonalcoholic fatty liver disease; NAFLD) or secondary cause. (3) Decompensated liver disease secondary to nonalcoholic steatohepatitis (NASH) is the second-most common indication for patients who undergo liver transplantation (LT). (4, 5) In 2014, it was the most common diagnosis for patients listed for transplantation. Because of this rapidly increasing incidence, the multidisciplinary management of obese patients with decompensated liver disease before, during, and after LT has become an important challenge. Before transplantation, obese patients have difficulty accessing transplant services. They are less likely to be placed on the waitlist, less likely to undergo transplantation once on the waitlist, and exhibit higher waitlist mortality (hazard ratio 5 1.16 in the most recent analysis), demonstrating that obese patients are disadvantaged on the transplant waiting list. (6, 7) This may be attributed, in part, to previous reports noting worse outcomes for obese patients, though more recent reports have noted no difference in patient or graft survival. (8) (9) (10) (11) (12) In the long term, metabolic and cardiovascular disease complications are a major cause of mortality post-LT. (13) This is particularly notable, considering that patients are carefully screened for cardiovascular disease pretransplant and those with significant disease are generally excluded from LT. Obesity before transplant and weight gain after LT have been associated with the development of metabolic syndrome (MetS) post-LT. (15) MetS and diabetes mellitus are major risk factors for cardiovascular events post-LT. (15) An additional concern for obese patients following LT is the development of recurrent or de novo NASH. (16) Weight reduction through lifestyle modifications has been shown to benefit obese patients with NASH; however, this is difficult to achieve and sustain, particularly for patients with long-standing, severe medically complicated obesity, as defined by a BMI 40 kg/m 2 or a BMI 35 kg/m 2 in the presence of major obesityrelated comorbidities. (17) (18) (19) Bariatric surgery has been shown to be effective in achieving weight loss and in reducing obesity-related comorbidities; however, patients with decompensated liver disease are at significantly increased risk for adverse outcomes following any elective surgical procedure and thus are typically not suitable to undergo bariatric surgery. In order to address the long-term risks of obesity in LT recipients, our group adopted a protocol in 2006, offering a lifestyle modification intervention for all patients with a BMI 35 kg/m 2 at listing. Patients who were successful with weight loss and achieved a BMI <35 and a Model for End-Stage liver Disease (MELD) score high enough to access transplantation underwent LT, whereas those who were unable to achieve a BMI <35 kg/m 2 but had a MELD score high enough to access transplantation were offered simultaneous LT and sleeve gastrectomy (LT 1 SG).
Sleeve gastrectomy (SG) is a restrictive procedure involving resection of the greater curvature of the stomach, with subsequent mechanical and hormonal effects providing excellent weight loss with low rate of complications. (20) This procedure was chosen because of its effectiveness, simplicity, and lack of malabsorptive properties. Additional benefits of SG over gastric bypass include more gradual weight loss and preserved access to the biliary tree for potential future interventions.
In a previous report, we presented our early experience among 7 patients who underwent LT 1 SG, showing that the simultaneous procedure is safe. (21) The aim of this report is to describe longer-term outcomes, including the dynamics of weight, impact on metabolic outcomes, and quality of life, among these patients after a mean follow-up of 5 6 2.4 years. We have also provided perioperative and short-term outcomes for our entire cohort of LT 1 SG patients.
Patients and Methods
All adult patients listed for LT since 2006 with BMI 35 kg/m 2 and at least one follow-up visit were enrolled in an aggressive weight management protocol, which has been described in our previous report. (22) The protocol consisted of dietary education provided by an experienced transplant dietician at the initial visit and at each subsequent visit until transplantation or achievement of goal weight. Patients were also evaluated by the same transplant surgeon at the initial and at each subsequent visit to assign a specific weight loss goal (generally BMI <35 kg/m 2 ), to further emphasize the long-term benefits of weight loss and to assess progress with weight loss. Patients were asked to:
1. Follow a calorie-restricted diet, generally 1,200-1,400 kcal for women and 1,400-1,600 kcal for men.
ARTICLE INFORMATION:
From The frequency of visits for obese patients in the noninvasive arm coincided with the scheduled follow-up with their transplant hepatologist and typically ranged from every 3 to 6 months. All patients with identified psychiatric issues were followed by a transplant center psychiatrist and further referred to psychology for counseling as appropriate. Activity recommendations were provided and further re-enforced at subsequent visits, and were tailored to meet individual activity restrictions and available resources. Patients with ascites had their weight measured after paracentesis. Those with edema greater than 11 on physical exam were considered to be at their goal weight when they were within 5 kg of target.
Patients who did not reach the target weight (BMI <35 kg/m 2 ) at the time of transplantation underwent combined LT 1 SG. These patients were assessed by the bariatric surgery team before surgery. All LT 1 SG were performed using deceased donors, with caval-sparing hepatectomy and duct-to-duct biliary anastomosis. The SG was performed by an experienced bariatric surgeon following completion of the LT utilizing a 9-mm endoscope or a 40-Fr bougie placed along the lesser curve of the stomach. A combination of 45-, 4.8-, and 60-mm 3.5 Endo-GIA staple loads were used to resect the antrum and greater curve. Care was taken to leave a small amount of cardia in place in order to avoid injury to the esophagus. The staple line was oversewn using a running 3-0 PDS suture. SG was aborted in 1 patient because of suspected tumor invasion of the diaphragm by hepatocellular carcinoma (HCC; this later turned out to be fibrotic reaction secondary to radiofrequency ablation). This patient was excluded from the analysis.
Management after transplant included dietician follow-up visits at 1, 4, and 12 months for the noninvasive weight loss program, and annually by the transplant center staff. Patients are counseled on a low-calorie diet plus exercise. Patients undergoing combined LT 1 SG are seen at 1, 4, and 12 months by the transplant surgeon, dietician, bariatric surgeon, endocrinologist, and psychologist, and then annually by the transplant center staff. Follow-up by bariatric team after 1 year is provided as needed. The initial postoperative diet consisted of clear liquid diet advancing to full liquids by day 3, pureed diet 3 3 weeks, soft diet 3 6 weeks, advancing to general diet by approximately 3 months. Patients are kept on a calorie count and with a minimum goal of 600-800 calories per day and an optimal goal of basal 3 75% during initial 4-6 weeks, and minimum of 60-80 g of protein per day, with protein powder supplementation as needed. Patients are also given calcium, iron, and vitamin supplementation (including B12 and D). The immunosuppression is standardized, and is the same for patients undergoing LT or LT 1 SG. All patients with a creatinine <2 who are not on dialysis receive tacrolimus 1 rapid steroid taper 1 MMF (mycophenolate mofetil). The MMF is stopped at 2 months and the prednisone taper is complete at 3 months. Patients with renal insufficiency/renal failure receive basiliximab 20 mg end on day 0 and on day 4, with a delayed introduction of tacrolimus. Initial target trough levels for tacrolimus are 7-10 ng/mL through month 2, then 5-8 ng/mL between 2 and 12 months post -LT, then 4-6 ng/mL after 1 year unless specific issues are noted such as posttransplant lymphoproliferative disorder, multiple rejection episodes, or intolerable side effects.
We included perioperative and short-term outcomes on all patients who underwent LT 1 SG. Only patients who were at least 3 years follow-up posttransplantation were included in the long-term outcome analysis. Weight and BMI changes were assessed using the percentage of total body weight loss (%TBWL), frequency of a 10% total body weight loss, and the percentage of excess BMI loss (%EBMIL; where BMI 5 25 is the normal value) (21) at listing, transplant, 4 months, 1, 2, and 3 years. Ascites was quantified at the time of transplant and the weight and BMI were adjusted according to its volume. At last follow-up, Adult Treatment Panel (ATP) III criteria was used to assess for MetS. (14) A BMI cutoff 30 kg/m 2 was used as a surrogate of waist circumference for the purpose of the ATP III criteria. The number of ATP III criterion was documented and MetS was diagnosed when three or more criteria were present. The number of drugs used to control diabetes, hypertension, and dyslipidemia were recorded.
Patients included after 2010 had serum determinations of insulin before listing and all patients included had yearly determination posttransplant. Homeostasis model assessment index for insulin resistance (HOMA-IR) was calculated using fasting glucose and insulin from the same day before listing and at last follow-up. (23) Hemoglobin A1c (Hb A1c ) was documented at listing and at last follow-up. A cutoff of 6.5% was used to compare between the cohorts, per the American Diabetes Association recommendations for Hb A1c monitoring. (24) Hepatic steatosis (HS) was defined through ultrasound, computed tomography (CT), or biopsy. All patients underwent ultrasound examination with Doppler at the scheduled follow-up appointments. HS using ultrasound was defined as a hyperechoic hepatic parenchyma (compared to renal cortex) with reduced visualization of the hepatic pedicles. On CT (performed if indicated based on symptoms or as part of postoperative screening for recurrent HCC in appropriate patients), HS was defined as a 10 Hounsfield unit difference between the liver and spleen in an unenhanced study (liver < spleen). (25) The questionnaire SF-12 version 2 was used to assess quality of life among patients through a phone interview. All patients were contacted by telephone at least three times to request participation in the telephone survey. The data were collected prospectively, and supplemented from medical record review, with approval from our Institutional Review Board. Statistical analysis was done using a chi-square test for categorical variables and t test for continuous variables. Data are presented as mean, SD, and 95% confidence interval (CI). We used SPSS software (v 22.0).
Results

PATIENT SAMPLE
Overall, there are 74 patients enrolled with 45 undergoing LT alone and 29 undergoing a combined LT 1 SG. Demographics and short-term outcomes for all patients who underwent a combined LT 1 SG are provided in Table 1 . Mean BMI at transplantation was 47 m 2 /kg, with a mean weight at transplantation of 135 kg. Mean BMI at last follow-up was 31 m 2 /kg. There was 1 patient intended for LT 1 SG who underwent LT alone and was excluded from further analysis.
In order to determine the long-term impact of this protocol, only patients with at least 3 years of posttransplant follow-up are included. Through July 2013, 49 patients have been transplanted in this protocol; for demographic data, see Table 2 . Fifty-five percent of the patients were female and the age average was 46.5 6 21.8 years. All LTs were performed using deceased donor livers; mean waiting time was 74.7 6 84.9 weeks. Mean weight at enrollment was 123.1 6 20.8 kg and mean BMI was 42.8 6 4.8. Thirty-six patients lost enough weight (21.0 6 12.8 kg) before transplant (BMI <35 kg/m 2 ) and continued lifestyle modifications after transplant (LT alone cohort). Thirteen patients were unable to achieve a BMI <35 at the time of transplant (weight loss 13.1 6 12.5 kg) and underwent simultaneous SG (LT 1 SG cohort). Patients in the LT alone cohort had a nonsignificant tendency to be older (55.4 6 7.8 vs. 50.7 6 7.4; P 5 0.067) and had a significantly lower weight (116.
LIVER DISEASE
NAFLD was present in 48.9% of the patients, with higher prevalence in the LT 1 SG cohort (LT cohort 44.4% vs. LT 1 SG cohort 76.9%; P 5 0.057). The diagnosis of NAFLD was based on having lack of secondary cause of liver disease, in the setting of metabolic comorbidities including obesity, diabetes, and hyperlipidemia. Although biopsy was not performed to confirm the NAFLD diagnosis prior to transplant, the presence of steatosis in the explant was noted in 20 of 22 patients who underwent combined SG 1 LT with a diagnosis of NAFLD, compared to 9 of 16 with steatosis in the explant for those undergoing LT alone with the diagnosis of NAFLD. Other causes of liver disease included hepatitis C (9 cases), autoimmune hepatitis (AIH; 4 cases), perihilar cholangiocarcinoma (CCA; 2 cases associated with primary sclerosing cholangitis, 1 de novo, all in the LT cohort), alcoholic liver disease (ALD; 2 cases), primary biliary cirrhosis (PBC; 2 cases), polycystic kidney/liver disease (1 case), hepatic epithelioid hemangioendothelioma (1 case), acute liver failure (1 case), Budd-Chiari syndrome (1 case), and hereditary hemorrhagic telangiectasia (HHT; 1 case). Ascites was present in 55.1% of the patient sample at the time of transplant (LT alone 58.3% vs. LT 1 SG 46.2%; P 5 0.525); ascites volume at LT was not different between cohorts (LT alone 2.3 6 3.8 L vs. LT 1 SG 1.2 6 1.7 L; P 5 0.174).
Overall, 37% of patients underwent LT through MELD exception points, more commonly in the LT cohort (41.7% vs. 23.1% in the LT 1 SG cohort; P 5 0.322). Thus, the LT alone cohort had a lower biological MELD than the LT 1 SG (18.9 6 8.1 vs. 32.0 6 9.5; P < 0.001). Mean waiting time was highly variable and not significantly different between the cohorts (LT 74.1 6 83.3 weeks vs. LT 1 SG 76.3 6 92.6 weeks; P 5 0.942). A total of 23.1% of the patients in the LT 1 SG cohort had a waiting time less than 6 months (LT 8.3% vs. LT 1 SG 23.1%; P 5 0.321).
DYNAMIC OF WEIGHT CHANGES
The LT alone cohort experienced a significant weight loss pretransplant that was maintained at 4 months. These patients regained weight progressively afterward, until stabilizing 3 years posttransplantation.
Overall, there was no significant difference observed in the LT cohort between the BMI at listing and the BMI at 3 years (40.06 6 2.99 vs. 38.53 6 6.53; difference -1.52 6 5.46; P 5 0.138); there were 8 patients (22%) who maintained a BMI <35 3 years posttransplantation whereas 73.3% had a BMI >35 (6 patients had no 3-year BMI data). The LT 1 SG cohort exhibited a significant difference in the BMI at listing and the BMI at 3 years (49.0 6 4.6 vs. 30.9 6 13.2; difference -18.08 6 10.51; P 5 0.001).
Dynamic of weight change was significantly different between the two cohorts, as shown in Fig. 1 . %TBWL data are shown in Table 3 . As would be Mean BMI at TX was 47 m 2 /kg, mean weight at TX was 135 kg. Mean BMI at last follow-up was 31 m2/kg. Abbreviations: M, male; F, female; AlAT, alpha1-antitrypsin; AIH, autoimmune hepatitis; HCV, hepatitis C virus; HPS, hepatopulmonary syndrome; TX, transplantation; Wt, weight; f/u, follow-up; HAT, hepatic artery thrombosis; HD, hemodialysis.
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expected, the %TBWL was higher in the LT cohort at the time of transplant (17.7 6 10.5, 95% CI, 14.1-21.3 vs. LT 1 SG 9.1 6 7.6%, 95% CI, 4.5-13.7; P 5 0.004); however, %TBWL was statistically higher among the LT 1 SG cohort at all other time points posttransplant: 4 months (LT 20.9 6 11.7 vs. LT 1 SG 29.6 6 12.3; P 5 0.038), 1 year (LT 12.1 6 14.9%; P < 0.001), 2 years (LT 4.0 6 14.5 vs. 34.4 6 12.2%; P < 0.001), and 3 years (LT 3.9 6 13.3% vs. LT 1 SG 34.8 6 17.3%; P < 0.001). Among the LT 1 SG cohort, the maximum %TBWL was achieved at 1 year (%TBWL 36.3 6 12.0%; difference -6.6 6 10.9%; P 5 0.049). No statistically significant difference in weight was observed in the LT 1 SG cohort after 2 years (%TBWL 34.4 6 12.2%; difference 11.9 6 10.1%; P 5 0.562) and 3 years (%TBWL 36.9 6 17.4%; difference -1.9 6 21.5.%; P 5 0.81). The %TBWL was greater in the LT 1 SG than the LT cohort at all time points posttransplantation (Fig. 1) .
Four patients in the LT 1 SG cohort had weight recorded both at 3 and 4 years after transplant, showing that there was no significant difference in total body weight loss between these two points of followup though there was a trend in this small cohort toward weight gain (difference 13.7 6 3.4%; P 5 0.118). Twenty-two patients in the LT alone cohort had weight recorded at 3, 4, and 5 years, showing no significant difference in %TBWL in both comparisons (year 3 vs. year 4 difference -2.0 6 6.2, P 5 0.120; year 4 vs. year 5 difference -0.25 6 4.7, P 5 0.805.
MetS
Variables were assessed at last follow-up in all patients (Table 4) . MetS was present in 44.9% of the patients at last follow-up, with a nonstatistically significant higher prevalence among patients in the LT cohort (LT 52.8% vs. 23.1%; P 5 0.104). Among all patients, the mean number of positive ATP III criteria was 2.5 6 1.0; patients in the LT cohort had a significantly higher number of positive criteria (LT 2.83 6 1.0 vs. 1.9 6 0.9; P 5 0.008). The prevalence of hypertension after transplant was higher in the LT cohort (63.9% vs. 23.1%; P 5 0.021) and required more medications per patient for its control (LT 1.0 6 1.0 vs. LT 1 SG 0.3 6 0.7; P 5 0.023). The prevalence of hypoalphalipoproteinemia and/or hypertriglyceridemia after transplant was not significantly different (LT 69.4% vs. 53.8%; P 5 0.178), but patients in the LT cohort received more medications per patient for its control (0.4 6 0.6 vs. 0.1 6 0.2; P 5 0.01).
The prevalence of diabetes before transplant was not significantly different between cohorts (LT 52.8% vs. LT 1 SG 30.8%; P 5 0.209). There were 2 patients who developed diabetes after transplant in the LT cohort whereas there were no cases of de novo diabetes in the LT 1 SG cohort (Table 5 ). Among patients with diabetes, 38% of the patients in the LT cohort (8 of 21) were diet-controlled following transplantation, as were 50% of the patients with diabetes in the LT1SG cohort (2 of 4) at last follow-up. Insulin levels among patients in the LT cohort were significantly higher (LT 20.1 6 11.4 vs. LT 1 SG 8.6 6 3.9; P < 0.001), with higher insulin resistance (IR) indices 
FIG. 1.
Percentage of total body weight loss among patients who underwent medical therapy followed by LT (blue line) and those who underwent LT 1 SG (red line) at listing, transplant, 4 months, 1, 2, and 3 years.
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(HOMA-IR LT 6.6 6 4.8 vs. LT 1 SG 2.2 6 1.1; P < 0.001) at last follow-up. There were no differences in Hb A1c after transplant between cohorts (LT 5.7 6 0.8 vs. LT 1 SG 5.0 6 1.5; P 5 0.147) or on the prevalence of Hb A1c >6.5% (LT 23.5% vs. 8.3%; P 5 0.409) at last follow-up. Of 4 patients who underwent LT 1 SG and required insulin pre-LT, 2 eventually have required insulin again postoperatively though this was not required in the first year following LT. HS was identified on 55.1% of the patients at last available follow-up, either on imaging studies or through a clinically driven biopsy, with a significantly higher prevalence on the LT cohort (66.7% vs. 23.1%; P 5 0.01).
QUALITY OF LIFE
Overall response rate was 57%. More patients from the LT 1 SG cohort responded to the survey (11 of 13; 84%) compared to the LT cohort (17 of 36; 47%). The reasons for the patients' lack of reply were: patient unavailable/refused (n 5 8), relocated (n 5 8), or death (n 5 5). The results of the SF-12 questionnaire show no significant differences between the two cohorts in any of the categories available (Table 6 ).
SURVIVAL
One patient in the LT 1 SG cohort died from an unknown cause at home 2 years after transplantation without ongoing issues. Four patients died in the LT cohort after a mean of 2.8 years posttransplantation. Causes of death were mesenteric ischemia, bowel obstruction, metastatic adenocarcinoma of unknown primary, and allograft failure. Survival was not statistically different between the cohorts (Fig. 3) . 
Discussion
Weight gain after solid organ transplantation is a common finding, particularly during the first 6 months posttransplant. (24, 25) Patients who are overweight before transplant tend to gain more weight than lean patients. (26) The pathophysiology of the weight gain is not completely understood. One idea relates to immunosuppression, though our protocol includes rapid withdrawal of steroids and only patients with AIH receive long-term low-dose (2.5-5.0 mg) steroid therapy (2 patients in each cohort). A second hypothesis is the effect of denervating the liver. This hypothesis has been studied in animal models, showing that parasympathetic denervation results on changes in diet consumption, hypertriglyceridemia, IR, and hypercholesterolemia. (27) (28) (29) (30) Although there is conflicting evidence in the literature, (31) obese patients undergoing LT experience similar graft and patient survival, despite experiencing a higher morbidity, intensive care unit stay, hospital stay, and overall cost, (32) (33) (34) (35) independently of their MELD score at transplant. (36) Mortality post-LT in patients with obesity before transplant has been associated with cardiovascular events. (37) Based on these data and concern for technical challenges related to exposure, weight loss pre-LT is recommended by many centers. However, no prospective trial has evaluated the benefit of intentional weight loss on survival among LT recipients with obesity before or after transplant, though there is evidence to support a benefit of weight loss in the nontransplant population.
This study demonstrates that a lifestyle intervention achieved weight loss before transplant in a cohort of patients with medically complicated obesity awaiting LT. Those who achieved weight loss target (BMI <35) underwent LT alone, and those who did not underwent combined LT 1 SG. Both cohorts experienced some weight gain after 1 year of follow-up, though the amount of weight gain (as measured by the %TBWL) was higher in the LT cohort. These cohorts represent two relevant scenarios for which this study provides insight. Patients in the LT alone cohort had a lower baseline weight and BMI, which may have 
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influenced their ability to reach the goal of BMI <35 kg/m 2 , given that waiting time and total weight loss at transplant were similar between the cohorts. Furthermore, liver disease and the urgent need for transplantation may have overshadowed the goal of weight loss in the LT 1 SG cohort, as shown by their higher biological MELD score at transplant.
At last follow-up, the patients in the LT 1 SG cohort achieved and maintained a greater %TBWL and showed a lower prevalence of HS, hypertension, lower IR, and MetS components, and they required a lower number of antihypertensive medications and antidyslipidemia medications at last follow-up.
Our data suggest that intentional weight loss provides objective benefit in several modifiable cardiovascular risk factors. Despite the view of SG as a purely restrictive procedure, it may have metabolic effects that could partially explain the improvement in the variables analyzed in this study beyond weight loss. These effects include lower ghrelin serum levels, higher glucagon-like peptide-1 serum levels, an increase in postprandial rise of cholecystokinin and peptide YY serum levels, accelerated gastric emptying, and faster small bowel transit. (19) There is no prospective study in the literature comparing the combined LT 1 SG to SG after LT. Many case reports (38) (39) (40) (41) and two case series (42, 43) have described that laparoscopic and robotic-assisted sleeve gastrectomy post-LT are feasible. Combined surgery (LT 1 SG) represents a single operation and recovery process for the patient, thus avoiding a more hostile operative field attributed to adhesions and altered anatomy, as well as other potential barriers to weight loss surgery such as insurance coverage, or delays attributed to complications such as rejection, infection, or disease recurrence. The disadvantage of simultaneous surgery is the potential for increased complications as well as the difficulty for patients in adapting to the significant changes that result from two major operations. Patients undergoing LT 1 SG have to not only learn a new set of medications, but also modify their diet, especially in the first few months following surgery.
Quality of life was analyzed at last follow-up. More patients in the LT 1 SG cohort completed the survey. Although there was a trend toward better vitality and mental health composite in the LT 1 SG cohort, no significant differences were identified. Importantly, the LT 1 SG patients did not have an inferior QOL compared to patients with LT alone.
The weaknesses of our study must be acknowledged. Despite being the largest series described in the literature, our sample size is small (n 5 49, with 13 LT 1 SG cases) and time of follow-up is relatively short (mean 5.2 6 2.0 years) in order to detect the impact of weight loss on long-term survival. In addition, we do not have baseline markers of quality of life before LT 1 SG that would allow us to compare the same cohort over time, though because of the confounding factor of the morbidity of liver disease, these data would be difficult to interpret. Finally, the evaluation of MetS variables is complex in the population before transplant. Most of the patients experience systemic vasodilation attributed to portal hypertension and their lipid profile has profound changes; the incidence of MetS after transplant may reflect, in part, the recovery of a patient with MetS before transplant.
Despite these weaknesses, the current study demonstrates several key findings. First, 25% of patients with medically complicated obesity before transplant who achieve weight loss before transplantation and undergo LT alone can maintain their weight loss; second, despite their baseline characteristics, including a much higher BMI at enrollment, patients in the LT 1 SG cohort have a more profound and stable weight loss after transplant. Finally, the modifiable cardiovascular risk factor profile among patients in the LT 1 SG is more favorable at last follow-up; whereas the quality of life showed no significant differences between the cohorts. Given that obesity-related liver disease is now one of the most common indications for LT, a structured approach for obese transplant candidates is of increased importance. The combination of LT 1 SG is effective at achieving durable weight loss and improved metabolic parameters. Whether the optimal approach is a simultaneous LT 1 SG, or LT followed by SG in 4-12 months, and whether selected transplant recipients who achieve significant pretransplant weight loss should still be offered the simultaneous approach remains a potential question for further study.
